Introduction
Bcr is a protein that was originally identified through its involvement in the Philadelphia (Ph) chromosome translocation, which is found in chronic myelogenous and acute lymphoblastic leukemia (ALL). In these leukemias, the amino-terminal part of Bcr becomes fused to a carboxyl-terminal segment encoded by the Abl proto-oncogene, forming Bcr/Abl fusion proteins that show deregulated tyrosine kinase activity. Bcr consists of multiple domains, including a C-terminal GTPase-activating domain for the small GTPase Rac, a DH, a PH and a C2 domain. There are two major forms of Bcr/Abl. P210 contains all of the Bcr coding region except the domain encoding the GTPase-activating part of Bcr, whereas P190 includes only the amino-acid residues encoded by BCR exon 1 (reviewed in Heisterkamp and Groffen, 2001; Laurent et al., 2001) .
Bcr has a unique N-terminal end that is not present in the related Abr protein, and which is encoded by the first exon (reviewed in Heisterkamp and Groffen, 2001; Laurent et al., 2001 ). This part of Bcr within Bcr/Abl has an important contribution to the overall transforming activity of the fusion protein. The first 63 N-terminal residues of Bcr form a tetramerization domain, which mediates the formation of Bcr/Abl multimers with increased kinase activity (McWhirter et al., 1993; Zhao et al., 2002) . BCR exon 1 further encodes a region with serine/threonine kinase activity and contains binding domains for the tyrosine kinases Abl and Fes, and for 14-3-3 and Grb-2 (reviewed in Heisterkamp and Groffen, 2001; Laurent et al., 2001) . Interestingly, it has been shown that a segment including residues 64-413 encoded by BCR exon 1 can inhibit the Bcr/ Abl protein (Wang et al., 2001; Hawk et al., 2002) .
In search of physiologically relevant proteins that could transduce the oncogenic signal of Bcr/Abl, we performed a yeast two-hybrid screen with the entire Bcr protein. Interestingly, we here identify the serine/ threonine kinase CKIIa (Litchfield, 2003; Pinna, 2003) as a protein that specifically interacts with Bcr and Bcr/ Abl and is involved in the proliferation of Bcr/Ablexpressing cells. CKIIa has itself been implicated by multiple studies in tumorigenesis, including leukemia (i.e., Seldin and Leder, 1995; Kelliher et al., 1996; Landesman-Bollag et al., 1998; Rifkin et al., 1998) . Molecular strategies designed to interfere with the CKIIa-Bcr/Abl interaction could have therapeutic potential in the treatment of Bcr/Abl-positive leukemias, or in slowing down the growth of these malignant cells.
Results

Bcr and CKIIa interact in mammalian cells
To isolate signaling mediators of Bcr, a yeast two-hybrid screen was performed using the entire Bcr protein as bait. We identified the a catalytic subunit of protein kinase CKII, among others, as a protein that interacts with Bcr (see Materials and methods). To investigate whether these proteins form a complex in mammalian cells, we cotransfected HA-tagged CKIIa and GSTtagged Bcr into CHO cells. Bcr protein was precipitated using glutathione agarose and the presence of bound CKIIa was investigated by Western blotting. As shown in Figure 1a , lane 2, Bcr was efficiently precipitated using this method. In the cotransfection of Bcr and CKIIa, CKIIa was specifically and strongly co-precipitated with Bcr (lane 3). These results indicate that the interaction of CKIIa and Bcr also occurs in CHO cells overexpressing the two proteins.
To examine if we could detect complex formation between endogenous CKIIa and Bcr, we prepared lysates from mouse brain, a relatively abundant source of Bcr protein (Fioretos et al., 1995; Kaartinen et al., 2001) and also known to express CKIIa . We then immunoprecipitated CKIIa protein from the lysates, and examined the precipitate for the presence of Bcr. As shown in Figure 1b , Bcr was clearly co-precipitated with CKIIa, further demonstrating that the interaction between the two proteins also occurs in vivo.
CKIIa binds to Bcr exon 1 residues 242-413
Preliminary experiments suggested that CKIIa binds to residues encoded by BCR exon 1 (amino acids 1-426; not shown). To map the region interacting with CKIIa, we made constructs that encoded different segments of BCR exon 1. When we immunoprecipitated endogenous CKIIa from cells transfected with a construct encoding Bcr residues 1-413, the (1-413) polypeptide was clearly and specifically co-precipitated with CKIIa ( Figure 2 , lane 2). A construct lacking the N-terminal oligomerization domain of Bcr (lacking residues 1-53) also was able to form a complex with CKIIa (lane 6). However, a Bcr segment including residues 1-177 did not co-precipitate with CKIIa (not shown), and conversely, an immunoprecipitation using the Xpress tag included in the (1-177) construct failed to bring down CKIIa (lane 8). Similarly, a larger Bcr segment, including residues 1-242 did not bind to CKIIa (Figure 2 , lane 11). These results establish that CKIIa binds to Bcr through residues 242-413.
CKIIa forms a complex with P210 and P190 Bcr/Abl
Since CKIIa binds to residues 242-413 of Bcr, an interaction between CKIIa and the two forms of Bcr/ Abl fusion oncoproteins P210 and P190, via their respective Bcr moieties, was recognized as a possibility. To test this, we cotransfected P210 and P190 Bcr/Abl with HA-tagged CKIIa into COS-1 cells. As shown in Figure 3 (lysates, lanes 1 and 3), all proteins were clearly expressed. Immunoprecipitations of HA-tagged CKIIa using polyclonal anti-HA antibodies showed that CKIIa could be efficiently precipitated (Figure 3a , IP, bottom panel). Moreover, both P210 and P190 Bcr/Abl were co-precipitated with CKIIa (IP, lanes 1 and 3, top panel).
To test whether the interaction between Bcr/Abl and CKIIa also occurs at physiological levels of protein expression, we used lysates made from lymphoma of a P190 transgenic mouse that developed leukemia/ 1 and 3) or GST-expressing vector (lane 4). GST-proteins were collected using glutathione agarose beads (lanes 2-4), and the presence of co-precipitating CKIIa examined using anti-HAantibodies (bottom panel). Lane 1 contains 5 mg of total lysate. (b) Triton lysates prepared from mouse brain (1 mg of protein) were subjected to immunoprecipitation using anti-CKIIa or control antibodies, followed by detection of co-precipitated proteins using polyclonal goat anti-CKIIa or anti-Bcr (Bcr G-6) antibodies on a 4-20% gradient gel. 30 mg of total lysate was also loaded Figure 2 Endogenous CKIIa binds to amino-acid residues 242-413 of Bcr. Cells were transfected with the constructs indicated below each panel. Numbers refer to amino-acid residues. Immunoprecipitations were performed using polyclonal CKIIa antibodies (lanes 2, 6), control normal goat antiserum (lanes 1, 5), anti-Xpress antibodies (lanes 8, 11), or control normal mouse IgG (lanes 7, 10). Western blots were reacted with the antibodies indicated to the right of the panels, including polyclonal CKIIa, Bcr monoclonal G-6 and monoclonal Xpress. Astreriks indicate the locations of the Bcr deletion mutant proteins; note that in the CKIIa ips, Bcr (1-413) and (53-413) migrate as doublets, similar to the observation of Hawk et al. (2002) . Lanes 3, 4, 9 and 12 contain total lysates CKIIa interacts with Bcr and Bcr/Abl S Mishra et al lymphoma. These previously generated P190 Bcr/Abl transgenics reproducibly develop lymphoblastic leukemia/lymphoma (Heisterkamp et al., 1990; Voncken et al., 1992a, b) . Endogenous CKIIa was immunoprecipitated and the presence of coimmunoprecipitated P190 oncoprotein was clearly detected as shown in Figure 3b . These results demonstrate that CKIIa forms a complex with both P210 and P190.
Inhibition of CKIIa activity inhibits the growth of Bcr/Abl P190 and P210 expressing cells
Next, we sought to address possible downstream effects of the interaction of CKIIa with Bcr/Abl. For these experiments, we used the TonB.210 cell line with doxycycline-inducible P210 expression (Klucher et al., 1998) as well as P190 lymphoma cells. P210 expression was clearly visible in the TonB.210 cells upon treatment with doxycycline for 48 h ( Figure 4a , upper panel). The cells also clearly expressed detectable levels of endogenous CKIIa (Figure 4a , lower panel). We treated both induced and noninduced cells with 60 mM 4,5,6,7-tetrabromo-2-benzotriazole (TBB), the most specific inhibitor of CKIIa activity available to date (Sarno et al., 2002) . TBB was initially only tested in vitro and in plant cells (Battistutta et al., 2001; Sarno et al., 2001) ; however, a more recent study found 25-100 mM TBB to be effective in inhibiting the growth of T-cell lymphoma Jurkat cells (Ruzzene et al., 2002) . In general, cells induced for P210 expression grew slower and treatment with TBB caused reduction in cell proliferation for both induced and noninduced cells (compare Figure 4b , top and bottom panels). However, the growth of P210-expressing cells was significantly affected by TBB within 22 h and continued up to 33 h ( Figure 4b , bottom panel), whereas in the P210 nonexpressing cells, growth inhibition was detected only at 33 h ( Figure 4b , top panel). The difference in inhibition of proliferation between the two samples was maximal at 22 h: P210-expressing cells showed 33% inhibition compared to just 10% inhibition seen in P210 nonexpressing cells. Interestingly, neither noninduced nor induced BaF3 cells showed signs of increased cell death upon exposure to TBB, since a significant decrease in cell viability was not observed.
This experiment suggested that TBB affects the proliferation of cells expressing P210 Bcr/Abl. However, it does not accurately reflect the situation in Ph-positive acute lymphoblastic leukemia cells, in which Bcr/Abl is constitutively expressed at all times. To address this issue, we tested the effect of TBB on the PLC1 lymphoblastic lymphoma cells. TBB had no effect on the overall levels of total Bcr/Abl, or on tyrosine phosphorylation of P190 Bcr/Abl after 25, 34 or 48 h of treatment of the cells (not shown). However, the exposure of PLC1 cells to 60 mM TBB did significantly inhibit their proliferation over a period of 48 h (Figure 4c ). The cells did not undergo significant cell death, since the viable cell numbers did not decrease. TBB at 10 mM also inhibited the growth of PLC1, but the effect was much less pronounced (not shown). These results are in agreement with those obtained with the TonB.210 cells and clearly show that inhibition of CKIIa serine/threonine kinase activity inhibits the proliferation of B-lymphoid cells, expressing both P210 as well as P190 Bcr/Abl.
Inhibition of Bcr/Abl tyrosine kinase activity decreases CKIIa serine/threonine kinase activity Next, we asked whether the Bcr/Abl kinase activity affected that of CKIIa. We treated PLC1 lymphoblastic lymphoma cells with imatinib, an effective inhibitor of Bcr/Abl tyrosine kinase activity (Deininger et al., 2003) , and assayed CKIIa activity. As shown in Figure 5a , exposure of PLC1 cells to 5 mM STI-571 significantly inhibited Bcr/Abl P190, as measured by the marked reduction in the level of tyrosine-phosphorylated proteins detected in these cells. A concentration of 10 mM further reduced the overall phosphotyrosine levels.
CKIIa-specific peptide substrates have been previously identified. Moreover, CKIIa is a unique kinase in that it can utilize GTP as well as ATP as phosphate donor (Litchfield, 2003) . Therefore, we measured CKIIa kinase activity towards its specific peptide substrate in the presence of GTP, in lysates of PLC1 cells treated Figure 5b , inhibition of the P190 Bcr/Abl kinase significantly inhibited the serine/threonine kinase activity of CKIIa. A concentration of 5 mM also caused statistically significant inhibition of CKII activity, although the degree of inhibition was lower (not shown).
Discussion
We have shown that endogenous CKIIa binds to endogenous Bcr and endogenous Bcr/Abl P190, that is, the complex formation occurs in vivo where the proteins are not overexpressed but exist at physiological levels. Moreover, CKIIa forms a direct complex with Bcr (in yeast). The region in Bcr that binds CKIIa corresponds to the residues encoded by exon 1, present in all forms of Bcr/Abl proteins. Thus, all forms of Bcr/Abl contain one domain that directly binds CKIIa.
As a whole, exon 1 of BCR encodes a number of interesting domains, which have been studied in detail by others. For example, the N-terminal oligomerization domain is critical in activating the Abl kinase in Bcr/Abl because it allows oligomerization of Bcr/Abl proteins and formation of Bcr-Bcr/Abl complexes (McWhirter et al., 1993; Zhao et al., 2002) . However, because CKIIa does not bind to this region, it is unlikely to affect the oligomerization of Bcr and Bcr/Abl.
We mapped the CKIIa binding site to residues 242-413 of Bcr. This area encompasses the Bcr serine/ threonine kinase domain, and the binding site for 14-3-3 and Abl. Abl binds to this region via its SH2 domain and in a phosphotyrosine-independent manner (Pendergast et al., 1991; Ma et al., 1997; Ling et al., 2003) . It is thus possible that CKIIa sterically hinders the binding of the Abl SH2 domain to Bcr. Also, Wang et al. (2001) showed that overexpression of a segment containing Bcr residues 64-413 interfered with cellular proliferation of CML patients' cells and two Ph-positive cell lines. Since this segment binds to CKIIa, our results suggest that its growth-inhibitory properties may be related, in part, to the sequestration of endogenous CKIIa. A previous study by Heriche and Chambaz (1998) reported that c-Abl forms a complex with CKIIa in NIH 3T3 cells. As we found that CKIIa interacts with the segment of Bcr that also binds to Abl, we considered the possibility that the binding of Abl to CKIIa, as found by Heriche and Chambaz, is indirect, through Bcr. We tested this by immunoprecipitating CKIIa from lysates prepared from brain of bcr wild-type and bcr À/À mice. Abl was co-precipitated with CKIIa in both samples, suggesting that the interaction between Abl and CKIIa is direct (results not shown). Therefore, one Bcr/Abl protein could, in principle, bind two CKIIa molecules.
One consequence of the binding of CKIIa to Bcr/Abl could be the tyrosine phosphorylation of the former. Heriche and Chambaz (1998) reported that bacterially produced v-Abl kinase can phosphorylate CKIIa in vitro on tyrosine. However, we found no evidence for tyrosine phosphorylation of endogenous murine CKIIa in a P190 Bcr/Abl lymphoma (results not shown), even though we could show a complex formation between the two proteins in such lysates. One possible explanation for these discrepant results is that with purified recombinant proteins, some specificity of phosphorylation may be lost. A second explanation could be that Heriche and Chambaz used chicken CKIIa for their studies, whereas we examined tyrosine phosphorylation of murine CKIIa. Although CKIIa is well conserved among species, chicken CKIIa contains a tyrosine residue, Y 323 within a sequence preferred by the Abl kinase (YxxP; Songyang et al., 1994) , but this residue is absent from murine CKIIa and in human CKIIa the sequence is Y 323 xxT. Because of this, we conclude that tyrosine phosphorylation of murine or human CKIIa by Bcr/Abl is unlikely to regulate its activity.
However, Bcr/Abl does directly or indirectly regulate CKIIa activity. We demonstrated this by showing that the inhibition of the P190 tyrosine kinase activity using STI-571 inhibits the activity of the endogenous CKIIa serine/threonine kinase towards a peptide substrate. We did not detect changes in CKIIa levels in cells treated with imatinib, indicating that the downregulation of CKIIa activity occurs through mechanism(s) unrelated to the modulation of protein levels. This is in agreement with studies that favor the concept that CKIIa is regulated not via modulation of its protein levels but rather by changes in substrate availability as a consequence of changes in its cellular localization (Litchfield, 2003; Faust and Montenarh, 2000) .
Heriche and Chambaz (1998) also measured CKIIa activity in the presence of activated Abl. They did not see any changes in activity of bacterially expressed CKIIa following phosphorylation by v-Abl in vitro. When they used transient transfection of HA-tagged chicken CKIIa with or without Bcr/Abl in serum-starved NIH3T3 fibroblasts however, they found that the transfection of Bcr/Abl did inhibit CKII activity. In contrast, we found that inhibition of Bcr/Abl inhibited CKIIa activity. These disparate results are difficult to compare because very different experimental conditions were used: at least in other systems, outcome of growth factor independence and transformation studies by Bcr/Abl have been shown to be cell-type-and assay-dependent (Ghaffari et al., 1999) . Similar to our study, others have also found a transformation-stimulatory cooperation between CKIIa and other oncogenes. Donella-Deanne et al. (2003) showed that the src-related tyrosine kinases, c-Fgr and Lyn, stimulated CKIIa activity in Jurkat cells. Orlandini et al. (1998) reported that Balb 3T3 fibroblasts were only transformed by coexpression of CKIIa and H-Ras but not when either was expressed alone. Moreover, CKIIa transgenic mice develop lymphomas (Seldin and Leder, 1995) . CKIIa also cooperates with other tumor-associated genes such as p53 and c-myc to accelerate lymphoma development and leukemogenesis in transgenic mice models (Seldin and Leder, 1995; Kelliher et al., 1996; Landesman-Bollag et al., 1998; Rifkin et al., 1998; Xu et al., 1999a) . Our own results support the concept of a cooperation between Bcr/Abl and CKIIa, in concordance with what is known about the positive role of both Bcr/Abl and CKIIa in leukemia.
It is commonly accepted that CKIIa plays an important role in cellular decisions regarding cell survival and death, although its precise mode of regulation has not been clearly defined. It was shown to prevent apoptosis, stimulate cell cycle and cell survival (reviewed by Litchfield, 2003; Pinna, 2003) . Other studies directly CKIIa interacts with Bcr and Bcr/Abl S Mishra et al point to a role for CKIIa in cell proliferation (Wang et al., 2000; Lebrin et al., 2001) . Our own results show that CKIIa is either directly or indirectly involved in the proliferation of P190 Bcr/Abl-expressing cells by a mechanism not apparently related to cell death: the very selective inhibitor of CKIIa, TBB, prevented the P190 lymphoma cells from proliferating without causing them to lose viability over a period of at least 33 h. On the one hand, this suggests that TBB is not very toxic to cells in general. This may be explained by the narrow specificity of TBB for only inhibiting one kinase, CKIIa. On the other hand, additional studies will be needed to evaluate whether this compound would be useful in selective eradication of rapidly proliferating Bcr/Ablexpressing cells. Since null mutants for the related protein, CKIIa 0 , are fully viable (Xu et al., 1999b) , this type of kinase activity appears to be nonessential. Thus, TBB may be minimally toxic in an entire organism and could have clinical applications to treat Ph-positive leukemias.
Materials and methods
Yeast two-hybrid screen
The bait vector pAS2-1 was digested with EcoRl Â BamHI. The entire Bcr coding region was inserted into this vector as a 1.6 kb EcoRI-SstI þ 1.0 kb SstI-HindIII þ a 1.6 kb HindIIIBamHI fragment. The 5 0 EcoRI and 3 0 BamHI sites were from the polylinkers of vectors. The resulting protein was in-frame with the Gal4 coding sequence and contained six amino-acid residues N-terminal to the Bcr ATG codon. We screened a human placenta cDNA library (MATCHMAKER, Clontech) . Screening of this library with Bcr-pAS2-1 was essentially as described before (Haataja et al., 1998; Senadheera et al., 2001; de Langhe et al., 2002) . A screen of 7.8 Â 10 5 colonies yielded 447 his þ clones, of which 169 were lacz þ . The screen yielded eight different positives including the Bcr protein and previously identified Bcr-binding proteins 14-3-3 and the XBP protein (Reuther et al., 1994; Braselmann and McCormick, 1995; Takeda et al., 1999) . Clone 17.2 had an insert of around 2.4 kb and encompassed the complete human CKIIa coding region including 115 bp of 5 0 untranslated region. CKIIa bound specifically and strongly to Bcr, but did not react with the false-positive test lamin. The HA-CKIIa subclone made from the yeast two-hybrid positive misses the first 20 aminoacid residues of the protein.
DNA constructs
GST-Bcr was constructed by in-frame ligation of a 5 0 0.6 kb BamHI-SalI fragment containing part of exon 1 of BCR þ a 3 0 3.5 kb SalI-XbaI fragment encoding the rest of BCR into vector pLEF (Rudert et al., 1996) digested with BamHI Â XbaI). The 5 0 BamHI site originates from the pSK polylinker adjacent to the EcoRI site used to insert the complete BCR cDNA. This site allows an in-frame insertion of the complete Bcr coding region with the GST moiety. To construct GST-P210 and GST-P190, the 5 0 0.75 kb BamHISalI fragment containing the 5 0 end of BCR was ligated with a 6.3 kb SalI-EcoRI or a 7.8 kb SalI-EcoRI fragment containing the P190 or P210 3 0 end into pLEF digested with Bam-HI Â EcoRI. FLAG-Bcr exon 1 encoding residues 1-413 was constructed as follows: the FLAG tag was first introduced into pSK between the SmaI and EcoRI sites. Exon l Bcr was ligated as a 1.2 kb 5 0 BamHI-BglII fragment into the BamHI site of this plasmid; plasmids with the right orientation were isolated. The Bcr fragment included a 5 0 BamHI and EcoRI linker sites. The insert of pSK-Bcr exonl-FLAG was removed by EcoRI digestion followed by subcloning into pSG5 digested with EcoRI. Deletion mutants for BCR exon 1 were constructed as follows: A subclone of BCR exon 1 (originally a 1.1 kb E47III-BglII fragment) in pSK was digested with BamHI Â EcoRI and the cut fragment encoding residues 53-413 was subcloned into pcDNA.HisA. Plasmid pGEX2T-BCR expressing all BCR exon l-encoded residues as a GST fusion protein was digested with BamHI Â XmnI and the fragment encoding Bcr residues 1-177 was subcloned into pcDNA.HisC digested with Bam-HI Â EcoRV. pGEX2T-BCR was digested with BamHI Â XhoI and the fragment encoding residues 1-242 was ligated into pcDNA.HisC digested with BamHI Â XhoI.
Lysates and immunoprecipitations
CHO cells were transiently transfected with 2 mg pSG5-HACKIIa and/or 2 mg pLEF-GST-Bcr or pLEF-vector plasmid (Rudert et al., 1996) using Lipofectamine (Gibco/BRL). Pulldown reactions in CHO cells were performed essentially as described using 500 mg of protein (Senadheera et al., 2001) . COS-1 cells were transiently transfected with pSG5-HAtagged-CKIIa alone or with Bcr/Abl proteins (GST-Bcr/Abl P210, GST-Bcr/Abl P190) using Lipofectamine. Deletion mutants (2-3 mg DNA) or pcDNA vector were transfected to COS-1 cells.
Antibodies
Antibodies used include: anti-HA mouse monoclonal (USC Core Facility, clone 12ca5) and rabbit anti-HA polyclonal (Santa Cruz Biotech Y-11 sc-805); goat anti-CKIIa polyclonal (Santa Cruz Biotech sc-6479); anti-Bcr monoclonal (Calbiochem bcr Ab-2 clone 7C6); anti-Bcr G6 monoclonal (against residues 103-114; Santa Cruz Biotech sc-104), anti-Abl 3F12 monoclonal (Dr Ravi Salgia, Dana-Farber Cancer Institute, Boston, MA, USA); anti-Xpress monoclonal (Invitrogen), antiphosphotyrosine polyclonal (Transduction Laboratories) and monoclonal anti-Gst(12) (Santa Cruz Biotech sc-138). For control immunoprecipitations, the respective normal goat, rabbit or mouse IgG was used (Santa Cruz Biotech, sc-2028 , sc-2027 , s-2025 .
Bcr/Abl expressing cells, TBB growth inhibition
TonB.210 cells were maintained in RPMI 1640 supplemented with IL-3 (supplied as 10% conditioned medium from Wehi3B cells), 10% fetal bovine serum (Klucher et al., 1998) , 100 U/ml penicillin/streptomycin and 0.2 mg/ml G418. We used the cells within 1 week of thawing of freeze-downs. Induction was by addition of 1 mg/ml doxycycline and growth for 2 days.
PLC1 lymphoma cells were established from the lymphoma of a P190 BCR/ABL transgenic mouse. The P190 BCR/ABL transgenic mouse strain has been previously described (Heisterkamp et al., 1990; Voncken et al., 1992a, b) . A line of P190 BCR/ABL mice established from founder 623 has been bred to obtain animals that contained the transgene on both chromosomes.
A single-cell suspension was made from primary lymphoma by gently grinding the tissue between two microscope slides. Cells were grown in McCoys 5A modified medium (Gibco-BRL) supplemented with 15% heat-inactivated FCS, 110 mg/l sodium pyruvate, 2 mM L-glutamine, 100 U/ml penicillin/streptomycin, 10 ng/ml recombinant murine IL-3 (Calbiochem) and 50 mM b-mercaptoethanol on irradiated (10 000 rads) primary mouse embryonic fibroblast feeder cell layers. All experiments with PLC1 and TonB.210 cells were performed in the presence of IL-3.
The specific CKIIa inhibitor TBB has been previously described (Battistutta et al., 2001; Sarno et al., 2001) . TBB was dissolved at a concentration of 60 mM in DMSO and stored at À801C. TBB to a final concentration of 60 mM was added to the medium and viable cell counts were performed in triplicate at each time point using trypan blue exclusion to score viable cells.
Treatment of PLC1 cells with STI-571 and CKIIa Kinase assay
Imatinib (Novartis, Basel, Switzerland) was dissolved at a concentration of 0.25 M in sterile H 2 O and diluted to a concentration of 10 mM, prepared fresh each time. Imatinib to a final concentration of 10 mM was added to PLC1 cells in medium for 24 h. Lysates were freshly prepared from treated cells in Triton lysis buffer (25 mM sodium phosphate, 150 mM NaCl, 1% Triton X-100, 5 mM EDTA, pH 8.0 and 50 mM NaF), with freshly added protease and phosphatase inhibitors (10 mg/ml aprotinin and leupeptin, 1 mM NaVO 3 (activated), PMSF and pepstatin A).
Kinase reactions were performed on 10 mg of whole-cell lysate in the presence of 0.5 mM CKIla-specific peptide substrate ((Arg) 3 (Glu) 3 Thr(Glu) 3 , American Peptide Company) in kinase buffer (150 mM NaCl, 50 mM MOPS, pH 7.0, 20 mM MgCI 2 , 100 mM GTP and 0.2 mCi [ 32 P]gGTP in 50 ml). Kinase reactions were carried out in triplicate for 20 min at 301C. Reactions were stopped by spotting 10 ml of the reaction onto P81 Whatman paper and washing three times in 75 mM phosphoric acid.
